Marco Lanzillotta

Employment

• San Raffaele Hospital
  2016 - Present

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (42)

• Rituximab limits glucocorticoid use in IgG4-related disease: Real-world evidence from a large European cohort
  European Journal of Internal Medicine 2026 DOI: 10.1016/j.ejim.2026.106832
  +Save
• Distinctive Inflammatory Traits of Parvovirus B19 Infection Associated with Persisting Autoimmunity
  Viruses 2026 DOI: 10.3390/v18070774
  +Save
• Maintenance Treatment for Type 1 Autoimmune Pancreatitis: Effectiveness and Development of the PrescrAIP Relapse Prediction Model
  Marco Lanzillotta, Peter Mačinga, Jakob Lykke Poulsen +60 more
  Clinical Gastroenterology and Hepatology 2026 DOI: 10.1016/j.cgh.2025.09.005
  +Save
• Clinical outcomes of subglottic stenosis in granulomatosis with polyangiitis: results of an international multicentre observational study
  Rheumatology 2026 DOI: 10.1093/rheumatology/keag107
  +Save
• Bridging the gap: Phenotype-specific considerations for rituximab therapy in IgG4-related disease. Author's reply
  European Journal of Internal Medicine 2026 DOI: 10.1016/j.ejim.2025.106650
  +Save
• Effectiveness and safety of rituximab across the four phenotypes of IgG4-related disease: a European multi-center cohort study
  European Journal of Internal Medicine 2026 DOI: 10.1016/j.ejim.2025.106459
  +Save
• Activation state of peripheral T lymphocytes predicts response to abatacept in patients with IgG4-related disease
  European Journal of Internal Medicine 2025 DOI: 10.1016/j.ejim.2025.106573
  +Save
• Association of IgG4-related disease with human inborn errors of immunity
  Rheumatology 2025 DOI: 10.1093/rheumatology/keaf353
  +Save
• Adherence to United European Gastroenterology Guidelines on Diagnosis and Therapy of Immunoglobulin‐G4‐Related Digestive Disease
  United European Gastroenterology Journal 2025 DOI: 10.1002/ueg2.70081
  +Save
• Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study
  Rheumatology 2025 DOI: 10.1093/rheumatology/keaf201
  +Save
• B cell depletion after treatment with rituximab predicts relapse of IgG4-related disease
  Rheumatology 2025 DOI: 10.1093/rheumatology/keae248
  +Save
• Increased prevalence of malignancies in patients with IgG4-related disease: implications for clinical care
  Rheumatology 2025 DOI: 10.1093/rheumatology/keae243
  +Save
• Update on Autoimmune Pancreatitis and IgG4‐Related Disease
  United European Gastroenterology Journal 2025 DOI: 10.1002/ueg2.12738
  +Save
• Association of autoimmune pancreatitis and intraductal papillary mucinous neoplasm. A retrospective analysis from a tertiary care referral center
  Pancreatology 2024 DOI: 10.1016/j.pan.2024.02.014
  +Save
• Safety of Janus Kinase Inhibitors: A Real-World Multicenter Retrospective Cohort Study
  The Journal of Rheumatology 2023 DOI: 10.3899/jrheum.2023-0145
  +Save
• B-cell depletion with obinutuzumab for the treatment of IgG4-related disease
  European Journal of Internal Medicine 2023 DOI: 10.1016/j.ejim.2023.07.019
  +Save
• Role of systemic immunosuppression on subglottic stenosis in granulomatosis with polyangiitis: Analysis of a single-centre cohort
  European Journal of Internal Medicine 2023 DOI: 10.1016/j.ejim.2023.05.006
  +Save
• Association of IgG4-related disease and systemic rheumatic disorders
  European Journal of Internal Medicine 2023 DOI: 10.1016/j.ejim.2023.03.015
  +Save
• Incidence of endocrine and exocrine insufficiency in patients with autoimmune pancreatitis at diagnosis and after treatment: a systematic review and meta-analysis
  European Journal of Internal Medicine 2022 DOI: 10.1016/j.ejim.2022.03.014
  +Save
• Unraveling the relationship between autoimmune pancreatitis type 2 and inflammatory bowel disease: Results from two centers and systematic review of the literature
  United European Gastroenterology Journal 2022 DOI: 10.1002/ueg2.12237
  +Save